표적 단백질 분해 종양학 시장 보고서(2026년)

Targeted protein degradation oncology (PROTAC) is an advanced therapeutic strategy that removes disease-causing proteins by utilizing the body's natural protein degradation pathways. It is developed to selectively eliminate proteins involved in cancer initiation and progression instead of simply blocking their function. Targeted protein degradation oncology (PROTAC) is intended to enhance treatment effectiveness, address drug resistance challenges, and broaden the spectrum of cancer-associated proteins available for therapeutic targeting.

The primary types of targeted protein degradation oncology (PROTAC) include proteolysis-targeting chimeras (PROTACs), molecular glue degraders, lysosome-targeting chimeras (LYTACs), autophagy-targeting chimeras (AUTACs), and other types. Proteolysis-targeting chimeras (PROTACs) are heterobifunctional molecules designed to selectively degrade disease-causing proteins by recruiting them to the cellular ubiquitin-proteasome system. These therapies are categorized by stages including approved therapies, Phase III clinical, Phase II clinical, and preclinical research and discovery. They target therapeutic areas such as breast cancer, prostate cancer, hematological malignancies, lung cancer, and others and are utilized by pharmaceutical companies, biotechnology companies, contract research organizations (CROs), academic research institutes, and others.

Tariffs are influencing the targeted protein degradation oncology (PROTAC) market by increasing the cost of imported active pharmaceutical ingredients, specialized reagents, and advanced laboratory equipment used in drug discovery and clinical development. This is driving up research and production expenses across key segments such as proteolysis targeting chimeras (PROTACs), molecular glue degraders, and lysosome targeting chimeras, particularly during the preclinical and clinical trial phases. Regions including North America, Europe, and Asia-Pacific are facing disruptions in cross-border research collaboration and biotech supply chains. However, tariffs are also promoting localized biomanufacturing, regional R&D expansion, and strategic partnerships, which are expected to enhance long-term innovation resilience in oncology drug development.

The targeted protein degradation oncology (protac) market research report is one of a series of new reports from The Business Research Company that provides targeted protein degradation oncology (protac) market statistics, including targeted protein degradation oncology (protac) industry global market size, regional shares, competitors with a targeted protein degradation oncology (protac) market share, detailed targeted protein degradation oncology (protac) market segments, market trends and opportunities, and any further data you may need to thrive in the targeted protein degradation oncology (protac) industry. This targeted protein degradation oncology (protac) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The targeted protein degradation oncology (PROTAC) market size has grown exponentially in recent years. It will grow from $1.3 billion in 2025 to $1.63 billion in 2026 at a compound annual growth rate (CAGR) of 26.0%. The growth in the historic period can be attributed to rising cancer prevalence globally driving demand for novel therapeutics, limitations of traditional small molecule inhibitors in oncology treatment, growth in targeted cancer therapy research and clinical trials, increasing investment in biotechnology and pharmaceutical r&d, expansion of precision medicine approaches in oncology care.

The targeted protein degradation oncology (PROTAC) market size is expected to see exponential growth in the next few years. It will grow to $4.14 billion in 2030 at a compound annual growth rate (CAGR) of 26.2%. The growth in the forecast period can be attributed to increasing adoption of next generation protein degradation platforms in oncology pipelines, rising demand for therapies targeting undruggable cancer proteins, expansion of biomarker driven personalized cancer treatment approaches, growing clinical validation of PROTAC based therapeutics, increasing pharmaceutical partnerships and biotech innovation funding. Major trends in the forecast period include ai driven protein degradation target discovery platforms for oncology drug design optimization, precision oncology expansion through tumor specific proteolysis targeting chimera development, next generation molecular glue degraders for overcoming cancer drug resistance mechanisms, advanced lysosome targeting chimera systems for selective cancer cell protein elimination, hybrid multi modal protein degradation therapies combining PROTAC and autophagy pathways.

The increasing incidence of cancer is expected to drive the growth of the targeted protein degradation oncology (PROTAC) market in the coming years. Cancer incidence refers to the occurrence rate of newly diagnosed cancer cases within a particular population during a specified period. The growing prevalence of cancer is primarily attributed to an aging population, as older individuals experience prolonged exposure to carcinogenic factors and a gradual decline in cellular repair processes. The increasing cancer burden is fueling the demand for innovative and highly targeted therapeutic approaches, as traditional treatments often struggle to effectively address undruggable oncoproteins, creating the need for selective degradation technologies such as targeted protein degradation oncology (PROTAC). For instance, in February 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, global cancer cases were projected to exceed 35 million new cases by 2050, reflecting a 77% rise from the estimated 20 million cases reported in 2022. Therefore, the rising incidence of cancer is contributing to the expansion of the targeted protein degradation oncology (PROTAC) market.

Leading companies operating in the targeted protein degradation oncology (PROTAC) market are concentrating on the development of advanced solutions, including oral PROTAC protein degraders, to improve therapeutic effectiveness, enhance patient convenience, and address previously undruggable cancer-driving proteins. Oral PROTAC protein degraders are orally delivered therapeutic agents that selectively trigger the breakdown of disease-associated proteins by utilizing the body's natural protein degradation pathways. For instance, in February 2024, Arvinas Inc., a US-based clinical-stage biotechnology company, collaborated with Pfizer Inc., a US-based biopharmaceutical and biotechnology corporation, to announce that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for the evaluation of vepdegestrant (ARV-471). This designation supports the accelerated development and regulatory review of a novel targeted protein degrader for treating ER+/HER2- locally advanced or metastatic breast cancer with significant unmet medical needs. Vepdegestrant (ARV-471) is a PROTAC protein degrader developed to selectively target and eliminate the estrogen receptor (ER), rather than only blocking its function.

In November 2023, Bristol Myers Squibb, a US-based biopharmaceutical company, acquired the ORM-6151 program from Orum Therapeutics for an undisclosed amount. Through this acquisition, Bristol Myers Squibb aims to strengthen its oncology pipeline and enhance its protein degradation capabilities by advancing a first-in-class anti-CD33 antibody-enabled GSPT1 degrader for the treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS). Orum Therapeutics is a US-based clinical-stage biotechnology company focused on developing dual-precision targeted protein degradation (TPD2) and targeted protein stabilization (TPS2) technologies for cancer therapies.

Major companies operating in the targeted protein degradation oncology (protac) market report are AbbVie Inc., Amgen Inc., Amphista Therapeutics Limited, Arvinas Inc., AstraZeneca plc, BeiGene Ltd., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, C4 Therapeutics Inc., Dialectic Therapeutics Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, Foghorn Therapeutics Inc., Gilead Sciences Inc., GSK plc, Johnson & Johnson, Kymera Therapeutics Inc., Merck & Co. Inc., Monte Rosa Therapeutics Inc., Novartis AG, Nurix Therapeutics Inc., Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited

North America was the dominating region in the targeted protein degradation oncology (PROTAC) market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the targeted protein degradation oncology (PROTAC) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the targeted protein degradation oncology (PROTAC) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The targeted protein degradation oncology (PROTAC) market consists of revenues earned by entities by providing services such as drug discovery support, targeted protein degradation platform development, oncology clinical research, and biomarker identification services. The market value includes the value of related goods sold by the service provider or included within the service offering. The targeted protein degradation oncology (PROTAC) market also includes sales of androgen receptor degraders, estrogen receptor degraders, bromodomain protein degraders, and kinase-targeting degraders. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Targeted Protein Degradation Oncology (PROTAC) Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses targeted protein degradation oncology (protac) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for targeted protein degradation oncology (protac) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The targeted protein degradation oncology (protac) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Proteolysis Targeting Chimeras (PROTACs); Molecular Glue Degraders; Lysosome Targeting Chimeras (LYTACs); Autophagy Targeting Chimeras (AUTACs); Other Types
• 2) By Stage: Approved Therapies; Phase III Clinical; Phase II Clinical; Preclinical Research And Discovery Stage
• 3) By Therapeutic Area: Breast Cancer; Prostate Cancer; Hematological Malignancies; Lung Cancer; Other Therapeutic Areas
• 4) By End User: Pharmaceutical Companies; Biotechnology Companies; Contract Research Organizations (CROs); Academic Research Institutes; Other End Users
• Subsegments:
• 1) By Proteolysis Targeting Chimeras (PROTACs): Small Molecule Proteolysis Targeting Chimeras (PROTACs); Peptide Based Proteolysis Targeting Chimeras (PROTACs); Antibody Conjugated Proteolysis Targeting Chimeras (PROTACs); Oral Proteolysis Targeting Chimeras (PROTACs) Therapeutics; Tumor Specific Proteolysis Targeting Chimeras (PROTACs)
• 2) By Molecular Glue Degraders: Small Molecule Molecular Glues; Protein Interaction Modulating Molecular Glues; Kinase Targeted Molecular Glues; Transcription Factor Degrading Molecular Glues; Oncology Specific Molecular Glue Degraders
• 3) By Lysosome Targeting Chimeras (LYTACs): Antibody Based Lysosome Targeting Chimeras (LYTACs); Glycoprotein Based Lysosome Targeting Chimeras (LYTACs); Cell Surface Receptor Mediated Lysosome Targeting Chimeras (LYTACs); Tumor Antigen Targeting Lysosome Targeting Chimeras (LYTACs)
• 4) By Autophagy Targeting Chimeras (AUTACs): Small Molecule Autophagy Targeting Chimeras (AUTACs); Organelle Specific Autophagy Targeting Chimeras (AUTACs); Protein Aggregate Targeting Autophagy Targeting Chimeras (AUTACs); Cancer Selective Autophagy Targeting Chimeras (AUTACs)
• 5) By Other Types: Hybrid Protein Degradation Modalities; Emerging Targeted Protein Degradation Platforms; Dual Mechanism Protein Degraders; Experimental Oncology Protein Degradation Technologies; Next Generation Targeted Degradation Systems
• Companies Mentioned: AbbVie Inc.; Amgen Inc.; Amphista Therapeutics Limited; Arvinas Inc.; AstraZeneca plc; BeiGene Ltd.; Boehringer Ingelheim International GmbH; Bristol-Myers Squibb Company; C4 Therapeutics Inc.; Dialectic Therapeutics Inc.; Eli Lilly and Company; F. Hoffmann-La Roche AG; Foghorn Therapeutics Inc.; Gilead Sciences Inc.; GSK plc; Johnson & Johnson; Kymera Therapeutics Inc.; Merck & Co. Inc.; Monte Rosa Therapeutics Inc.; Novartis AG; Nurix Therapeutics Inc.; Pfizer Inc.; Sanofi S.A.; Takeda Pharmaceutical Company Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Targeted Protein Degradation Oncology (PROTAC) Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Targeted Protein Degradation Oncology (PROTAC) Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Targeted Protein Degradation Oncology (PROTAC) Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Targeted Protein Degradation Oncology (PROTAC) Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Artificial Intelligence & Autonomous Intelligence
  • 4.1.2 Biotechnology, Genomics & Precision Medicine
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Immersive Technologies (AR/VR/XR) & Digital Experiences
• 4.2. Major Trends
  • 4.2.1 AI Driven Protein Degradation Target Discovery Platforms For Oncology Drug Design Optimization
  • 4.2.2 Precision Oncology Expansion Through Tumor Specific Proteolysis Targeting Chimera Development
  • 4.2.3 Next Generation Molecular Glue Degraders For Overcoming Cancer Drug Resistance Mechanisms
  • 4.2.4 Advanced Lysosome Targeting Chimera Systems For Selective Cancer Cell Protein Elimination
  • 4.2.5 Hybrid Multi Modal Protein Degradation Therapies Combining PROTAC And Autophagy Pathways

5. Targeted Protein Degradation Oncology (PROTAC) Market Analysis Of End Use Industries

• 5.1 Pharmaceutical Companies
• 5.2 Biotechnology Companies
• 5.3 Contract Research Organizations (CROs)
• 5.4 Academic Research Institutes
• 5.5 Other End Users

6. Targeted Protein Degradation Oncology (PROTAC) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Targeted Protein Degradation Oncology (PROTAC) Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Targeted Protein Degradation Oncology (PROTAC) PESTEL Analysis (Political, Economical, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Targeted Protein Degradation Oncology (PROTAC) Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Targeted Protein Degradation Oncology (PROTAC) Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Targeted Protein Degradation Oncology (PROTAC) Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Targeted Protein Degradation Oncology (PROTAC) Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Targeted Protein Degradation Oncology (PROTAC) Market Segmentation

• 9.1. Global Targeted Protein Degradation Oncology (PROTAC) Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Proteolysis Targeting Chimeras (PROTACs), Molecular Glue Degraders, Lysosome Targeting Chimeras (LYTACs), Autophagy Targeting Chimeras (AUTACs), Other Types
• 9.2. Global Targeted Protein Degradation Oncology (PROTAC) Market, Segmentation By Stage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Approved Therapies, Phase III Clinical, Phase II Clinical, Preclinical Research And Discovery Stage
• 9.3. Global Targeted Protein Degradation Oncology (PROTAC) Market, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Breast Cancer, Prostate Cancer, Hematological Malignancies, Lung Cancer, Other Therapeutic Areas
• 9.4. Global Targeted Protein Degradation Oncology (PROTAC) Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations (CROs), Academic Research Institutes, Other End Users
• 9.5. Global Targeted Protein Degradation Oncology (PROTAC) Market, Sub-Segmentation Of Proteolysis Targeting Chimeras (PROTACs), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Small Molecule Proteolysis Targeting Chimeras (PROTACs), Peptide Based Proteolysis Targeting Chimeras (PROTACs), Antibody Conjugated Proteolysis Targeting Chimeras (PROTACs), Oral Proteolysis Targeting Chimeras (PROTACs) Therapeutics, Tumor Specific Proteolysis Targeting Chimeras (PROTACs)
• 9.6. Global Targeted Protein Degradation Oncology (PROTAC) Market, Sub-Segmentation Of Molecular Glue Degraders, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Small Molecule Molecular Glues, Protein Interaction Modulating Molecular Glues, Kinase Targeted Molecular Glues, Transcription Factor Degrading Molecular Glues, Oncology Specific Molecular Glue Degraders
• 9.7. Global Targeted Protein Degradation Oncology (PROTAC) Market, Sub-Segmentation Of Lysosome Targeting Chimeras (LYTACs), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Antibody Based Lysosome Targeting Chimeras (LYTACs), Glycoprotein Based Lysosome Targeting Chimeras (LYTACs), Cell Surface Receptor Mediated Lysosome Targeting Chimeras (LYTACs), Tumor Antigen Targeting Lysosome Targeting Chimeras (LYTACs)
• 9.8. Global Targeted Protein Degradation Oncology (PROTAC) Market, Sub-Segmentation Of Autophagy Targeting Chimeras (AUTACs), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Small Molecule Autophagy Targeting Chimeras (AUTACs), Organelle Specific Autophagy Targeting Chimeras (AUTACs), Protein Aggregate Targeting Autophagy Targeting Chimeras (AUTACs), Cancer Selective Autophagy Targeting Chimeras (AUTACs)
• 9.9. Global Targeted Protein Degradation Oncology (PROTAC) Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hybrid Protein Degradation Modalities, Emerging Targeted Protein Degradation Platforms, Dual Mechanism Protein Degraders, Experimental Oncology Protein Degradation Technologies, Next Generation Targeted Degradation Systems

10. Targeted Protein Degradation Oncology (PROTAC) Market Regional And Country Analysis

• 10.1. Global Targeted Protein Degradation Oncology (PROTAC) Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Targeted Protein Degradation Oncology (PROTAC) Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Targeted Protein Degradation Oncology (PROTAC) Market

• 11.1. Asia-Pacific Targeted Protein Degradation Oncology (PROTAC) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Targeted Protein Degradation Oncology (PROTAC) Market, Segmentation By Type, Segmentation By Stage, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Targeted Protein Degradation Oncology (PROTAC) Market

• 12.1. China Targeted Protein Degradation Oncology (PROTAC) Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Targeted Protein Degradation Oncology (PROTAC) Market, Segmentation By Type, Segmentation By Stage, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Targeted Protein Degradation Oncology (PROTAC) Market

• 13.1. India Targeted Protein Degradation Oncology (PROTAC) Market, Segmentation By Type, Segmentation By Stage, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Targeted Protein Degradation Oncology (PROTAC) Market

• 14.1. Japan Targeted Protein Degradation Oncology (PROTAC) Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Targeted Protein Degradation Oncology (PROTAC) Market, Segmentation By Type, Segmentation By Stage, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Targeted Protein Degradation Oncology (PROTAC) Market

• 15.1. Australia Targeted Protein Degradation Oncology (PROTAC) Market, Segmentation By Type, Segmentation By Stage, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Targeted Protein Degradation Oncology (PROTAC) Market

• 16.1. Indonesia Targeted Protein Degradation Oncology (PROTAC) Market, Segmentation By Type, Segmentation By Stage, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Targeted Protein Degradation Oncology (PROTAC) Market

• 17.1. South Korea Targeted Protein Degradation Oncology (PROTAC) Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Targeted Protein Degradation Oncology (PROTAC) Market, Segmentation By Type, Segmentation By Stage, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Targeted Protein Degradation Oncology (PROTAC) Market

• 18.1. Taiwan Targeted Protein Degradation Oncology (PROTAC) Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Targeted Protein Degradation Oncology (PROTAC) Market, Segmentation By Type, Segmentation By Stage, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Targeted Protein Degradation Oncology (PROTAC) Market

• 19.1. South East Asia Targeted Protein Degradation Oncology (PROTAC) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Targeted Protein Degradation Oncology (PROTAC) Market, Segmentation By Type, Segmentation By Stage, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Targeted Protein Degradation Oncology (PROTAC) Market

• 20.1. Western Europe Targeted Protein Degradation Oncology (PROTAC) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Targeted Protein Degradation Oncology (PROTAC) Market, Segmentation By Type, Segmentation By Stage, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Targeted Protein Degradation Oncology (PROTAC) Market

• 21.1. UK Targeted Protein Degradation Oncology (PROTAC) Market, Segmentation By Type, Segmentation By Stage, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Targeted Protein Degradation Oncology (PROTAC) Market

• 22.1. Germany Targeted Protein Degradation Oncology (PROTAC) Market, Segmentation By Type, Segmentation By Stage, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Targeted Protein Degradation Oncology (PROTAC) Market

• 23.1. France Targeted Protein Degradation Oncology (PROTAC) Market, Segmentation By Type, Segmentation By Stage, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Targeted Protein Degradation Oncology (PROTAC) Market

• 24.1. Italy Targeted Protein Degradation Oncology (PROTAC) Market, Segmentation By Type, Segmentation By Stage, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Targeted Protein Degradation Oncology (PROTAC) Market

• 25.1. Spain Targeted Protein Degradation Oncology (PROTAC) Market, Segmentation By Type, Segmentation By Stage, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Targeted Protein Degradation Oncology (PROTAC) Market

• 26.1. Eastern Europe Targeted Protein Degradation Oncology (PROTAC) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Targeted Protein Degradation Oncology (PROTAC) Market, Segmentation By Type, Segmentation By Stage, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Targeted Protein Degradation Oncology (PROTAC) Market

• 27.1. Russia Targeted Protein Degradation Oncology (PROTAC) Market, Segmentation By Type, Segmentation By Stage, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Targeted Protein Degradation Oncology (PROTAC) Market

• 28.1. North America Targeted Protein Degradation Oncology (PROTAC) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Targeted Protein Degradation Oncology (PROTAC) Market, Segmentation By Type, Segmentation By Stage, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Targeted Protein Degradation Oncology (PROTAC) Market

• 29.1. USA Targeted Protein Degradation Oncology (PROTAC) Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Targeted Protein Degradation Oncology (PROTAC) Market, Segmentation By Type, Segmentation By Stage, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Targeted Protein Degradation Oncology (PROTAC) Market

• 30.1. Canada Targeted Protein Degradation Oncology (PROTAC) Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Targeted Protein Degradation Oncology (PROTAC) Market, Segmentation By Type, Segmentation By Stage, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Targeted Protein Degradation Oncology (PROTAC) Market

• 31.1. South America Targeted Protein Degradation Oncology (PROTAC) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Targeted Protein Degradation Oncology (PROTAC) Market, Segmentation By Type, Segmentation By Stage, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Targeted Protein Degradation Oncology (PROTAC) Market

• 32.1. Brazil Targeted Protein Degradation Oncology (PROTAC) Market, Segmentation By Type, Segmentation By Stage, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Targeted Protein Degradation Oncology (PROTAC) Market

• 33.1. Middle East Targeted Protein Degradation Oncology (PROTAC) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Targeted Protein Degradation Oncology (PROTAC) Market, Segmentation By Type, Segmentation By Stage, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Targeted Protein Degradation Oncology (PROTAC) Market

• 34.1. Africa Targeted Protein Degradation Oncology (PROTAC) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Targeted Protein Degradation Oncology (PROTAC) Market, Segmentation By Type, Segmentation By Stage, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Targeted Protein Degradation Oncology (PROTAC) Market Regulatory and Investment Landscape

36. Targeted Protein Degradation Oncology (PROTAC) Market Competitive Landscape And Company Profiles

• 36.1. Targeted Protein Degradation Oncology (PROTAC) Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Targeted Protein Degradation Oncology (PROTAC) Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Targeted Protein Degradation Oncology (PROTAC) Market Company Profiles
  • 36.3.1. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Amphista Therapeutics Limited Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Arvinas Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

37. Targeted Protein Degradation Oncology (PROTAC) Market Other Major And Innovative Companies

• BeiGene Ltd., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, C4 Therapeutics Inc., Dialectic Therapeutics Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, Foghorn Therapeutics Inc., Gilead Sciences Inc., GSK plc, Johnson & Johnson, Kymera Therapeutics Inc., Merck & Co. Inc., Monte Rosa Therapeutics Inc., Novartis AG

38. Global Targeted Protein Degradation Oncology (PROTAC) Market Competitive Benchmarking And Dashboard

39. Upcoming Startups in the Market

40. Key Mergers And Acquisitions In The Targeted Protein Degradation Oncology (PROTAC) Market

41. Targeted Protein Degradation Oncology (PROTAC) Market High Potential Countries, Segments and Strategies

• 41.1 Targeted Protein Degradation Oncology (PROTAC) Market In 2030 - Countries Offering Most New Opportunities
• 41.2 Targeted Protein Degradation Oncology (PROTAC) Market In 2030 - Segments Offering Most New Opportunities
• 41.3 Targeted Protein Degradation Oncology (PROTAC) Market In 2030 - Growth Strategies
  • 41.3.1 Market Trend Based Strategies
  • 41.3.2 Competitor Strategies

42. Appendix

• 42.1. Abbreviations
• 42.2. Currencies
• 42.3. Historic And Forecast Inflation Rates
• 42.4. Research Inquiries
• 42.5. The Business Research Company
• 42.6. Copyright And Disclaimer